Figure 1.

Flowchart showing identification of patients with ICI colitis. Clinical diagnositic criteria for ICI colitis included diarrheal symptoms, consistent stool studies, discontinuation of ICI therapy, treatment with steroids or other immunosuppressive therapy, and exclusion of other colitis etiologies. Nivolumab was used as a single agent in 133 patients, either as a second or later line therapy (n=127) or in the context of a clinical trial (n=6). ICI: immune checkpoint inhibitor, mRCC: metastatic renal cell carcinoma, IBD: inflammatory bowel disease.